HOME >> MEDICINE >> NEWS
Heart failure medication does not improve survival, compared to more widely used medication

The drug levosimendan did not improve survival for patients with decompensated heart failure when compared with a more widely-used treatment for this condition, dobutamine, according to a study in the May 2 issue of JAMA.

Acute decompensated heart failure (ADHF; severe heart failure characterized by inability of the heart to maintain adequate blood circulation) remains a common cause of hospitalization worldwide, but appropriate treatment is not always clear. Dobutamine improves symptoms but has been associated with an increased risk of death and other cardiovascular events, according to background information in the article. In a previous study, secondary analyses indicated that the drug levosimendan was associated with lower risk of death compared to dobutamine.

Alexandre Mebazaa, M.D., Ph.D., of the Universit Paris Diderot and Hospital Lariboisire AP-HP, Paris, and colleagues with the SURVIVE trial (Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support) conducted a study in which the primary purpose of the trial was to assess long-term survival outcomes for 1,327 ADHF patients who received levosimendan or dobutamine. The trial was conducted at 75 centers in 9 countries and patients were randomized between March 2003 and December 2004. Patients received either intravenous levosimendan (n = 664) or intravenous dobutamine (n = 663).

The researchers found that during the 180 days after drug infusion, there were 173 deaths (26 percent) in the levosimendan group and 185 deaths in the dobutamine group (28 percent). There were no statistical differences between treatment groups for most secondary end points (all-cause death at 31 days, number of days alive and out of the hospital, patient global assessment, patient assessment of dyspnea (difficulty breathing) at 24 hours, and cardiovascular death at 180 days). Compared with dobutamine-treated patients, levosimendan-treated patients were less likely to expe
'"/>

Contact: Katherine Morales
214-648-3404
JAMA and Archives Journals
1-May-2007


Page: 1 2

Related medicine news :

1. Drug-eluting stent controversy explored in the American Heart Hospital Journal
2. Heart-failure patients benefit from pharmacist care
3. Study offers clues to Broken Heart Syndrome
4. Heart Failure 2007
5. UCLA neurologist honored with American Heart Associations Stroke Council Award
6. Heart failure: Mayo Clinic reveals abnormality in filling of the heart is frequent culprit
7. Heart catheters do not benefit patients
8. Heart Rhythm Society publishes final recommendations for heart patients
9. Heartburn drug may help to slow progression of chronic heart failure
10. Heart failure drugs may be beneficial for patients with hardening of the arteries
11. University of Kentucky Gill Heart researchers study abdominal aortic aneurysms

Post Your Comments:
(Date:5/20/2013)... When people have lap ... become a celebrity. New Jersey governor Chris Christie, ... report (“Chris Christie Says Lap Band Surgery Is ... surgery was not done so that he could ... as a former lap band patient. Simply put, ...
(Date:5/20/2013)... Fountain Valley, CA (PRWEB) May 20, 2013 ... few dental professionals certified and trained to use the ... surgery designed to treat patients with gum disease. ... already lost teeth due to gum disease restore the ... disease begins with the buildup of plaque and tartar ...
(Date:5/20/2013)... 20, 2013 Mombo from Comfort ... conference of the US Lactation Consultant Association (USLCA) May ... nurses, doctors and other health professionals. , The ... helping lactation professionals discover and learn about the latest ... the most popular nursing pillows, which new mothers use ...
(Date:5/20/2013)... According to a May 6, 2013 CBS News article, ... tanning salons in the US may soon have to ... to see cancer warnings on indoor tanning beds ... for the use of indoor tanning and sun beds. The ... increasingly common over the last few decades (Go to goo.gl/TCT6m). ...
(Date:5/20/2013)... According to a June 2009 Bloomberg article, it ... to approximately $3.6 billion dollars per year (i). ... that there 15 million incidents of medical harm each ... who receives any form of medical treatment should be ... defines malpractice as “a dereliction of professional duty or ...
Breaking Medicine News(10 mins):Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 3Health News:Fountain Valley, Ca Gum Disease Patients with Missing Teeth Can Now Receive Laser Gum Surgery from Dr. Robert Mokbel for Success with Dental Implants 2Health News:Comfort & Harmony™ Exhibited mombo™ Nursing Pillow at USLCA’s First Inaugural Conference 2Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2Health News:Law Firm Releases New Informational Graphic on the Basics of Understanding Medical Malpractice Cases 2
(Date:5/20/2013)... , May 20, 2013  Neuralstem, Inc. (NYSE ... , MD, PhD, principal investigator, presented updated Phase ... cell (NSI-566) trial in the treatment of amyotrophic lateral ... disease) at the neuro diabetes special medical symposium in ... a talk called "Recent Therapeutic Advances in Stem Cell ...
(Date:5/20/2013)... 2013  AbbVie (NYSE: ABBV ) ... clinical study called SONAR (Study Of Diabetic Nephropathy ... investigational compound atrasentan - when added to standard of ... with stage 2 to 4 chronic kidney disease ... large, multinational, double-blind, placebo-controlled clinical study that is ...
(Date:5/20/2013)... 20, 2013 With herbal medicines relied upon ... the U.S. Pharmacopeial Convention (USP) will provide freely available ... herbal ingredients used in these products. Today, USP proposes ... new Herbal Medicines Compendium ( HMC ) ... hmc.usp.org . HMC will provide ...
Breaking Medicine Technology:Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 2New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 3
Cached News: